The Influence of the Severity of Chronic Virus-Related Liver Disease on Propofol Requirements during Propofol-Remifentanil Anesthesia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study was to investigate the influence of chronic virus-related liver disease severity on propofol requirements. Materials and Methods:In this study, 48 male patients with chronic hepatitis B infection were divided into three groups according to Child-Turcotte-Pugh classification of liver function (groups A, B, and C with mild, moderate and severe liver disease, respectively). After intubation, propofol concentration was adjusted by ±0.3 μg/mL increments to maintain bispectral index in the range of 40-60. Target propofol concentrations at anesthesia initiation, pre-intubation and pre-incision were recorded. Results: The initial concentration used in group C was significantly lower than that used in group A or B (p<0.05), whereas no difference was observed between groups A and B. At pre-intubation, the actual required concentration of propofol increased significantly (3.2 μg/mL) in group A (p<0.05), which lead to significant differences between the groups (p<0.05). At pre-incision, the requirements for propofol decreased significantly in both groups A and B (3.0 μg/mL and 2.7 μg/mL, respectively) compared with those at pre-intubation (p<0.05), and were significantly different for all three groups (p<0.05), with group C demonstrating the lowest requirement (2.2 μg/mL). The required concentrations of propofol at pre-incision were similar to those at induction. Conclusion: In this study, propofol requirements administered by target-controlled infusion to maintain similar depths of hypnosis were shown to depend on the severity of chronic virus-related liver dysfunction. In other words, patients with the most severe liver dysfunction required the least amount of propofol.
Abstract
Purpose: The purpose of this study was to investigate the influence of chronic virus-related liver disease severity on propofol requirements. Materials and Methods:In this study, 48 male patients with chronic hepatitis B infection were divided into three groups according to Child-Turcotte-Pugh classification of liver function (groups A, B, and C with mild, moderate and severe liver disease, respectively). After intubation, propofol concentration was adjusted by ±0.3 μg/mL increments to maintain bispectral index in the range of 40-60. Target propofol concentrations at anesthesia initiation, pre-intubation and pre-incision were recorded. Results: The initial concentration used in group C was significantly lower than that used in group A or B (p<0.05), whereas no difference was observed between groups A and B. At pre-intubation, the actual required concentration of propofol increased significantly (3.2 μg/mL) in group A (p<0.05), which lead to significant differences between the groups (p<0.05). At pre-incision, the requirements for propofol decreased significantly in both groups A and B (3.0 μg/mL and 2.7 μg/mL, respectively) compared with those at pre-intubation (p<0.05), and were significantly different for all three groups (p<0.05), with group C demonstrating the lowest requirement (2.2 μg/mL). The required concentrations of propofol at pre-incision were similar to those at induction. Conclusion: In this study, propofol requirements administered by target-controlled infusion to maintain similar depths of hypnosis were shown to depend on the severity of chronic virus-related liver dysfunction. In other words, patients with the most severe liver dysfunction required the least amount of propofol.
참고문헌 (32)
- Ziser A, "Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery", Curr Opin Anaesthesiol, 14, pp.707~711 (2001)
- Servin F, "Pharmacokinetics of propofol infusions in patients with cirrhosis", Br J Anaesth, 65, pp.177~183 (1990)
- Schnider TW, "The influence of age on propofol pharmacodynamics", Anesthesiology, 90, pp.1502~1516 (1999)
- Schüttler J, "Population pharmacokinetics of propofol: a multicenter study", Anesthesiology, 92, pp.727~738 (2000)
- Irwin MG, "Propofol effective concentration 50 and its relationship to bispectral index", Anaesthesia, 57, pp.242~248 (2002)
- Johnson KB, "Influence of hemorrhagic shock followed by crystalloid resuscitation on propofol: a pharmacokinetic and pharmacodynamic analysis", Anesthesiology, 101, pp.647~659 (2004)
- Xu Z, "C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial", Anesth Analg, 108, pp.478~483 (2009)
- Wu J, "Plasma propofol concentrations during orthotopic liver transplantation", Acta Anaesthesiol Scand, 49, pp.804~810 (2005)
- Takizawa D, "Changes in apparent systemic clearance of propofol during transplantation of living related donor liver", Br J Anaesth, 95, pp.643~647 (2005)
- Amorós A, "Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy", Gastrointest Endosc, 70, pp.262~268 (2009)
- Riphaus A, "Propofol sedation for upper gastrointestinal endoscopy in patients with liver cirrhosis as an alternative to midazolam to avoid acute deterioration of minimal encephalopathy: a randomized, controlled study", Scand J Gastroenterol, 44, pp.1244~1251 (2009)
- Pugh RN, "Transection of the oesophagus for bleeding oesophageal varices", Br J Surg, 60, pp.646~649 (1973)
- Marsh B, "Pharmacokinetic model driven infusion of propofol in children", Br J Anaesth, 67, pp.41~48 (1991)
- Struys MM, "Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol", Anesthesiology, 92, pp.399~406 (2000)
- Minto CF, "Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development", Anesthesiology, 86, pp.10~23 (1997)
- Chernik DA, "Validity and reliability of the Observer’s Assessment of Alertness", Sedation Scale: study with intravenous midazolam, 1990, pp.10, 244~251
- Veselis RA, "Performance of computer-assisted continuous infusion at low concentrations of intravenous sedatives", Anesth Analg, 84, pp.1049~1057 (1997)
- Khamaysi I, "Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: a randomized controlled study", J Hepatol, 54, pp.72~77 (2011)
- Wang CH, "Bispectral index monitoring in healthy, cirrhotic, and end-stage liver disease patients undergoing hepatic operation", Transplant Proc, 40, pp.2489~2491 (2008)
- Li Z, "ED50 and recovery times after propofol in rats with graded cirrhosis", Anesth Analg, 114, pp.117~121 (2012)
- Milne SE, "Propofol sparing effect of remifentanil using closed-loop anaesthesia", Br J Anaesth, 90, pp.623~629 (2003)
- Koitabashi T, "Remifentanil dose", electroencephalogram bispectral response during combined propofol, Anesth Analg, pp.2002, 94[DOI]
- Gan TJ, "Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil, and nitrous oxide anesthesia. BIS Utility Study Group", Anesthesiology, 87, pp.808~815 (1997)
- Bauer M, "Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery", Anesthesiology, 101, pp.1096~1104 (2004)
- Dershwitz M, "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease", Anesthesiology, 84, pp.812~820 (1996)
- Navapurkar VU, "Metabolism of remifentanil during liver transplantation", Br J Anaesth, 81, pp.881~886 (1998)
- Lichtenbelt BJ, "Strategies to optimise propofol-opioid anaesthesia", Clin Pharmacokinet, 43, pp.577~593 (2004)
- Wang LP, "Low and moderate remifentanil infusion rates do not alter target-controlled infusion propofol concentrations necessary to maintain anesthesia as assessed by bispectral index monitoring", Anesth Analg, 104, pp.325~331 (2007)
- Iwakiri H, "Individual effect-site concentrations of propofol are similar at loss of consciousness and at awakening", Anesth Analg, 100, pp.107~110 (2005)
- Wakeling HG, "Targeting effect compartment or central compartment concentration of propofol: what predicts loss of consciousness?", Anesthesiology, 90, pp.92~97 (1999)
- Minto CF, "Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics", Anesthesiology, 99, pp.324~333 (2003)
- Vuyk J, "Pharmacodynamics of propofol in female patients", Anesthesiology, 77, pp.3~9 (1992)